Share This Author
Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine
Comparative Affinity of Duloxetine and Venlafaxine for Serotonin and Norepinephrine Transporters in vitro and in vivo, Human Serotonin Receptor Subtypes, and Other Neuronal Receptors
Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication.
Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex
Comparing the ability of five systemically administered selective serotonin uptake inhibitors to increase acutely the extracellular concentrations of serotonin, norepinephrine and dopamine in rat prefrontal cortex suggests that fluoxetine is an atypical SSRI.
LY248686, A New Inhibitor of Serotonin and Norepinephrine Uptake
- D. Wong, F. Bymaster, Douglas A. Mayle, L. R. Reid, J. Krushinski, D. Robertson
- Biology, ChemistryNeuropsychopharmacology
LY248686 has a favorable pharmacological profile as a potential antidepressant drug because of its lack of affinity for receptors of 5-HT, NE, DA, acetylcholine, histamine and naloxone, and its ability to inhibit 5- HT and NE uptake simultaneously.
Synergistic Effects of Olanzapine and Other Antipsychotic Agents in Combination with Fluoxetine on Norepinephrine and Dopamine Release in Rat Prefrontal Cortex
Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum
It is demonstrated that in the case of sequential dosing olanzapine more effectively enhances DA and NE release in the Pfc than in the subcortical areas, which may have an impact on its atypical antipsychotic actions.
A selective inhibitor of serotonin uptake: Lilly 110140, 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine.
Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors.
- H. Shannon, F. Bymaster, P. Sauerberg
- Biology, MedicineThe Journal of pharmacology and experimental…
- 1 April 1994
The present data are consistent with the interpretation that xanomeline is a novel muscarinic receptor agonist with functional selectivity for M1 mus carinic receptors both in vitro and in vivo.